Photo from wikipedia
Proton pump inhibitors (PPIs) are often prescribed to prevent or treat gastrointestinal disease. Whether the combination of systemic anti‐tumour therapy and PPIs leads to poor outcomes in patients with advanced… Click to show full abstract
Proton pump inhibitors (PPIs) are often prescribed to prevent or treat gastrointestinal disease. Whether the combination of systemic anti‐tumour therapy and PPIs leads to poor outcomes in patients with advanced non‐small cell lung cancer (NSCLC) is unclear. This systematic review explored the relationship between PPIs and survival outcomes of patients with advanced NSCLC who are receiving systemic anti‐tumour therapy.
Keywords:
outcomes patients;
tumour therapy;
systemic anti;
patients advanced;
anti tumour
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!